Stockreport

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

Aprea Therapeutics, Inc.  (APRE) 
PDF Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose levelPatient experienced only Grade 1 adverse events Represents second patient [Read more]